Genetic Characteristics of Metastatic Breast Cancer Patients
- Conditions
- Metastatic Breast Cancer
- Interventions
- Diagnostic Test: Genomic analysis
- Registration Number
- NCT04258735
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Genomic analysis for metastatic breast cancer(MBC) patients
* Participant (Inclusion criteria)
1. Patients who diagnosed metastatic/stage IV breast cancer
2. Patients who were not received treatment for metastatic breast cancer on palliative setting
* Process
(1) Tissue/ Blood sample
* At diagnosis, MBC tissue / blood sample (20cc) will be obtained.
* At disease progression after 1st line treatment for MBC, blood sample (20cc) will be obtained (tissue; optional)
(2) WES, RNASeq, ctDNA, Exosome
* We will analyze genomic characteritics using WES, RNASeq, ctDNA, Exosome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 300
- Patients who diagnosed ad metastatic breast cancer
- Patients who were not received treatment on palliative setting
- Patients who did not agree this study
- Patients who did not have any pathologic specimen at MBC diagnosis.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Metastatic breast cancer cohort Genomic analysis Metastatic breast cancer with genetic tests including WES, RNASeq, ctDNA and exosome
- Primary Outcome Measures
Name Time Method Genomic profiling of MBC patients 60 months Gemetic alteration frequency, the association between genetic alteration and survival
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Samsung Medical Center, Sungkyunkwan University School of Medicine
🇰🇷Seoul, Korea, Republic of